Ypsomed To Supply Autoinjectors To Novo Nordisk Under Long-Term Agreement

Swiss medical technology company Ypsomed YPHDF announced a long-term supply deal with Novo Nordisk A/S NVO for autoinjectors.

Novo has been unable to keep pace with demand for Wegovy, which uses autoinjectors.

Also Read: Novo Nordisk Partners With South Africa-Based Aspen To Supply Insulin For African Countries.

The autoinjectors will be used by people self-administering drugs to treat various metabolic indications, Ypsomed said, adding that the pens were "for various drugs currently undergoing clinical trials."

Ypsomed said it would expand its manufacturing capacities over the coming years, with Novo Nordisk contributing a significant part of the investment for the additional production infrastructure.

A first step with significant capacity for manufacturing YpsoMate autoinjectors will be available for Novo Nordisk in 2025.

 In order to reduce dependencies, third-party manufacturers will also get the right to manufacture under a royalty scheme.

Ypsomed will manufacture autoinjectors for Novo's "second-generation GLP-1s", which are currently in clinical trials, Ypsomed's head of investor relations, Thomas Kutt, told Reuters.

"We will deliver autoinjectors for this upcoming device, which may be available in two or three years on the market," he said.

Price Action: NVO shares are up 2.39% at $95.75 on the last check Wednesday.